We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Modified Adenovirus Vector Used for Cancer Gene Therapy

By LabMedica International staff writers
Posted on 15 Feb 2018
Print article
Image: An adenovirus without and with a novel protein shield. The adenovirus (left) was camouflaged from the immune system by the protective coat (right) (Photo courtesy of the University of Zurich).
Image: An adenovirus without and with a novel protein shield. The adenovirus (left) was camouflaged from the immune system by the protective coat (right) (Photo courtesy of the University of Zurich).
A team of medical virologists has modified the commonly used adenovirus vector to both avoid clearance by the immune system and liver and to specifically target and invade tumor cells.

The clinical application of most systemic viral gene therapies has been limited by the efficient neutralization of the viruses by the immune system and their rapid elimination by the liver. Furthermore, adenovirus has been of little use in the realm of cancer therapy, as this virus does not normally invade tumor cells.

Investigators at the University of Zurich (Switzerland) developed a "work-around" to empower an adenovirus vector for use as a carrier for cancer gene therapy. They engineered a high-affinity protein coat that shielded the most commonly used vector in clinical gene therapy, human adenovirus type 5. Using electron microscopy and crystallography they demonstrated a massive coverage of the virion surface through the hexon-shielding scFv fragment, which was trimerized to exploit the hexon symmetry and gain avidity. In addition, the shield reduced virion clearance in the liver.

When the shielded particles were equipped with adaptor proteins, the virions delivered their payload genes into human cancer cells expressing the HER2 or EGFR surface proteins.

The investigators further reported in the January 31, 2018, online edition of the journal Nature Communications that the combination of shield and adapter also increased viral gene delivery to xenografted tumors in vivo, reduced liver off-targeting, and minimized immune neutralization.

"With this gene shuttle, we have opened up many avenues to treat aggressive cancers in the future, since we can make the body itself produce a whole cocktail of therapeutics directly in the tumor," said senior author Dr. Andreas Plueckthun, professor of biochemistry at the University of Zurich.

Related Links:
University of Zurich

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.